Results for this period
First quarter1 January 2026–31 March 2026ConsolidatedIFRSThe width of the band at each stage is based on revenue. The narrower it becomes toward the bottom, the smaller the proportion of revenue that remains as profit.
塗りつぶした部分が自己資本比率です。総資産のうち、返済のいらない自前の資金がどれだけかを表します。The thin vertical line indicates the level at the end of the previous fiscal year.
Stacked from zero: upward is an increase in cash, downward a decrease (in Millions of yen).The net change represented by the dotted line is the total of three items, calculated from figures provided by the company.
While product sales remain at an early stage, the company continues to make upfront investments in pharmaceutical development and other areas that exceed profits from product sales.
No applicable matters
| Item | Details |
|---|---|
| Fiscal Period Classification | First quarter |
| Accounting standards | IFRS |
| Consolidated / non-consolidated | Consolidated |
| Period Covered | 1 January 2026–31 March 2026 |
| Net Sales | 6 Millions of yen (YoY -75.1%) |
| Operating profit | -306 Millions of yen |
| Ordinary income | -306 Millions of yen |
| Profit attributable to owners of the parent | -307 Millions of yen |
| Net income per share | −¥1.14 |
| Equity ratio | End of the current fiscal period 85.7 / End of previous period 81.7 |
| Total assets | 1,992 Millions of yen |
| Net assets | 1,708 Millions of yen |
| Cash flows from operating activities | -63 Millions of yen |
| Cash flows from investing activities | -17 Millions of yen |
| Cash flows from financing activities | 251 Millions of yen |
| Cash and cash equivalents at end of period | 1,569 Millions of yen |
| Annual Dividend Forecast | ¥0 → ¥0 |
| Depreciation and amortization | 9 Millions of yen |
| Disclosure regarding the going concern assumption | No applicable matters |
| Change in accounting policy | Changes due to revisions to standards No / Other changes No / Change in accounting estimate No / Restatement Not disclosed |
| Changes in the scope of consolidation | New 0 companies / Excluded 0 companies / Company name None |
| Availability of Supplementary Financial Results Materials | No |
| Availability of Financial Results Briefing | Event No / Subject person None |
| Issued Shares at Period-End | 273,414,365 |
| Treasury Shares at Period-End | 409,143 |
| Factors Behind Changes in Business Performance | While product sales remain at an early stage, the company continues to make upfront investments in pharmaceutical development and other areas that exceed profits from product sales. |
Items this document does not state (12)
These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.
The reasons the company gives
The company's own explanation, not something inferred from the numbers.Product sales remain at an early stage, while the company continues to make upfront investments in pharmaceutical development and other areas that exceed profits from product sales. In addition, revenue from licensing agreements is affected by factors that are difficult for the company to control, including negotiations with partners, the terms of agreements, partners' development policies and clinical trial results. As a result, the company considers it difficult to forecast the total amount.